Latest News on DVA

Financial News Based On Company


Advertisement
Advertisement

BrightSpring Health Services Drops 5.5% Amid Sector-Wide Selling

https://news.alphastreet.com/brightspring-health-services-drops-5-5-amid-sector-wide-selling/
BrightSpring Health Services (BTSG) experienced a 5.5% decline on Thursday, closing at $64.56 per share on volume of 1.2M shares. This drop was part of a broader selloff in healthcare stocks, with other major players like Cigna and DaVita also seeing significant declines, suggesting a sector-wide rotation rather than company-specific concerns. Investors are advised to monitor whether this trend continues or if the sector stabilizes, while also looking for any company-specific news that could shift the narrative.

DaVita Drops 5.5% Amid Sector-Wide Selling

https://news.alphastreet.com/davita-drops-5-5-amid-sector-wide-selling/
DaVita Inc. shares fell 5.5% due to a broad selloff across the medical care facility sector, with no company-specific news cited as a catalyst. Other sector peers like BTSG and HNGE also experienced declines, indicating a synchronized investor rotation out of the sector. The drop highlights volatility in healthcare services stocks influenced by macro factors rather than individual company developments.

DaVita Inc. stock outperforms competitors despite losses on the day

https://www.marketwatch.com/data-news/davita-inc-stock-outperforms-competitors-despite-losses-on-the-day-6834091c-bbf4939ed09f?mod=goog_fin_scmw
DaVita Inc. (DVA) shares fell 3.37% to $156.34 on Thursday, marking its fourth consecutive day of losses. This occurred during a grim trading session where the S&P 500 Index (SPX) dropped 2.02% and the Dow Jones Industrial Average (DJIA) fell 2.19%. Despite the daily loss, the article title suggests an outperformance against competitors, though specific comparative data is not provided in the body.

DaVita Inc (TRL.SG) Seasonal returns chart

https://uk.finance.yahoo.com/quote/TRL.SG/seasonality/
The article provides a seasonal returns chart for DaVita Inc (TRL.SG), showing its average monthly price return from 2016 to 2026. It indicates the stock's current performance with a slight dip of 0.77% as of 8:55:20 CET.

DaVita Inc. (DVA) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_3796_QuantitativeReport_1794960000000
Argus has lowered its target price for DaVita Inc. (DVA) to $164.00, citing the company's position as the largest provider of dialysis services in the U.S. with about 35% market share. The current stock price for DVA is $156.34. The report was published on November 18, 2026.
Advertisement

McKesson Corporation (MCK) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_3176_AnalystReport_1794855055000
Argus analyst David H. Toung has raised the target price for McKesson Corporation (MCK) stock, maintaining a "Buy" rating. The report, published on November 16, 2026, highlights McKesson's operations across North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical segments.

Form 4 DaVita Inc: Phyllis R. Yale (Director) For: 15 November

https://ng.investing.com/news/stock-market-news/form-4-davita-inc-phyllis-r-yale-director-for-15-november-93CH-2814878
This article reports on a Form 4 filing for DaVita Inc., detailing an insider transaction by director Phyllis R. Yale on November 15. The publication by Investing.com provides a brief notification of this financial activity.

Form 4 DaVita Inc: Jason M. Hollar (Director) For: 15 November

https://in.investing.com/news/stock-market-news/form-4-davita-inc-jason-m-hollar-director-for-15-november-93CH-5711653
This article from Investing.com reports on a Form 4 filing for DaVita Inc., specifically detailing a transaction by director Jason M. Hollar on November 15. The publication date of the article is November 18, 2026, at 01:16 pm. The article is brief and primarily serves as an announcement of the SEC filing.

Form 4 DaVita Inc: Adam H. Schechter (Director) For: 15 November

https://ca.investing.com/news/stock-market-news/form-4-davita-inc-adam-h-schechter-director-for-15-november-93CH-4965943
This article reports a Form 4 filing for DaVita Inc., indicating an insider transaction by Director Adam H. Schechter, occurring on November 15. The brief announcement provides no further details about the nature of the transaction.

Form 4 DaVita Inc: Javier Rodriguez (Director, CEO) For: 15 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-davita-inc-javier-rodriguez-director-ceo-for-15-november-93CH-5711646
This article reports on a Form 4 filing for DaVita Inc., indicating that Javier Rodriguez, who serves as both a Director and CEO, made a transaction on November 15th. Form 4 filings are used to report changes in beneficial ownership of a company's securities by its directors, officers, and principal stockholders. The article is a brief notification of this public disclosure.
Advertisement

Form 4 DaVita Inc: Javier Rodriguez (Director, CEO) For: 15 November

https://ca.investing.com/news/stock-market-news/form-4-davita-inc-javier-rodriguez-director-ceo-for-15-november-93CH-4965945
This article reports on a Form 4 filing for DaVita Inc., indicating an insider transaction involving Javier Rodriguez, who serves as a Director and CEO of the company. The filing pertains to activity that occurred on November 15. The brief serves as a notification of this regulatory disclosure.

Form 4 DaVita Inc: Javier Rodriguez (Director, CEO) For: 15 November

https://uk.investing.com/news/stock-market-news/form-4-davita-inc-javier-rodriguez-director-ceo-for-15-november-93CH-4989689
This article reports a Form 4 filing for DaVita Inc., indicating an insider transaction by Javier Rodriguez, who serves as a Director and CEO. The filing is specifically noted for November 15. The brief announcement provides no further details on the nature of the transaction.

Form 4 DaVita Inc: Barbara J. Desoer (Director) For: 15 November

https://uk.investing.com/news/stock-market-news/form-4-davita-inc-barbara-j-desoer-director-for-15-november-93CH-4989682
This article reports on a Form 4 filing for DaVita Inc., indicating an insider transaction by Director Barbara J. Desoer on November 15. The publication itself is a brief notification from Investing.com, providing no further details within the body of the text.

Form 4 DaVita Inc: Jason M. Hollar (Director) For: 15 November

https://ca.investing.com/news/stock-market-news/form-4-davita-inc-jason-m-hollar-director-for-15-november-93CH-4965938
This article reports a Form 4 filing for DaVita Inc., detailing a transaction by Director Jason M. Hollar on November 15. The publication by Investing.com provides a brief notification of this insider trading activity.

Director’s 286-share award at DaVita (DVA) was reported at $0 per share.

https://www.stocktitan.net/sec-filings/DVA/form-4-davita-inc-insider-trading-activity-9911f8432387.html
DaVita Inc. director Barbara J. Desoer was awarded 286 common shares on November 15, 2026, with a reported value of $0.00 per share. Following this transaction, her direct holding in the company is 286 shares, and she indirectly holds 14,299 shares through a trust. This insider transaction was filed with the SEC on November 17, 2026.
Advertisement

DaVita Expands Availability of Advanced Dialysis Therapy to Every U.S. Center

https://www.prnewswire.com/news-releases/davita-expands-availability-of-advanced-dialysis-therapy-to-every-us-center-302941122.html
DaVita has announced the nationwide availability of Expanded Hemodialysis (Expanded HD) at all its U.S. centers, a significant advancement in kidney care. This therapy removes a broader range of toxins than conventional dialysis, with 95% of eligible patients adopting it within two weeks of rollout. The goal is to improve patients' quality of life by reducing symptoms and supporting better recovery between treatments.

DaVita Expands Availability of Advanced Dialysis Therapy to Every U.S. Center

https://www.stocktitan.net/news/DVA/da-vita-expands-availability-of-advanced-dialysis-therapy-to-every-u-0reyvgjfx490.html
DaVita has made its advanced Expanded hemodialysis (Expanded HD) therapy available at all U.S. centers, allowing nationwide access to a treatment that removes a broader range of toxins. This therapy saw rapid adoption, with 95% of eligible patients prescribed Expanded HD within two weeks of its rollout. DaVita aims for this innovation to improve patient quality of life by reducing symptoms and is also evaluating other enhanced clearance options like high-volume hemodiafiltration.

Berkshire Hathaway 13F: Sales Outweighed Purchases; Swapping Bank of America Stock for Lennar

https://www.morningstar.com/stocks/berkshire-hathaway-13f-sales-outweighed-purchases-swapping-bank-america-stock-lennar
Berkshire Hathaway's latest 13F filing for the third quarter of 2026 shows that sales of equity holdings outweighed purchases, resulting in net sales of $426 million. This activity reflects a quicker-than-expected streamlining of the portfolio under new CEO Greg Abel, with notable sales including Bank of America and purchases of Lennar stock. The firm sold stakes historically attributed to Todd Combs and Ted Weschler, indicating a move towards fewer, more concentrated holdings.

Learn Why The Bull Case For Cigna Group Stock Could Change Following Quarterly Earnings

https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/learn-why-the-bull-case-for-cigna-group-stock-could-change-f
Cigna Group reported mixed Q3 2026 results with higher sales and revenue but lower net income, raising concerns about cost trends and margin pressure. Investors will closely scrutinize commentary from Cigna Group's CFO at the upcoming UBS Global Healthcare Conference for insights into business drivers and strategies to address profitability. The article highlights the tension between strong cash flows from Evernorth and Cigna Healthcare and the ongoing regulatory and cost pressures affecting the company's profitability.

Weekly Recap: Rising payment pressure and Washington noncompete suit

https://www.tradingview.com/news/tradingview:5e3f87bb43894:0-weekly-recap-rising-payment-pressure-and-washington-noncompete-suit/
DaVita Inc. (DVA) anticipates an increase in reimbursement pressure, expecting it to reach about $70 million by 2027, up from $40 million this year, due to fewer new dialysis patients having commercial insurance. The company is also facing a lawsuit from Washington regarding nephrologist noncompete agreements, which DaVita denies and plans to defend. Additionally, DaVita expects seasonal missed treatments to rise during flu season and is investing in AI while introducing new dialyzers to patients.
Advertisement

RDVA to KRW: DaVita Inc. Tokenized Stock (Reality) Price in South Korean Won

https://www.coingecko.com/en/coins/davita-inc-rstock/krw
This article provides the current and historical price of DaVita Inc. Tokenized Stock (Reality) (RDVA) in South Korean Won (KRW) on CoinGecko. As of the current date, 1 RDVA is valued at ₩232,405, showing minor daily fluctuations. The piece also includes conversion tables, market statistics, and frequently asked questions about trading RDVA.

DaVita Expects Fewer Dialysis Treatments in Q4, but Higher Revenue per Visit Could Help Offset the Drop

https://www.tradingview.com/news/marketbeat:c59cbd149094b:0-davita-expects-fewer-dialysis-treatments-in-q4-but-higher-revenue-per-visit-could-help-offset-the-drop/
DaVita (DVA) anticipates a sequential decline in Q4 dialysis treatments due to calendar effects and increased missed treatments from hospitalizations, which typically rise during flu season. However, Chief Financial Officer Joel Ackerman expects higher revenue per treatment to help offset this impact. The company also projects a significant sequential increase in its IKC business and continues to explore growth opportunities, including new dialyzers and international expansion.

DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law

https://www.businesswire.com/news/home/20261112529811/en/DVA-Investors-Have-Opportunity-to-Join-DaVita-Inc.-Fraud-Investigation-with-SBS-Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into DaVita Inc. (NYSE: DVA) for potential securities law violations. This follows an announcement by the U.S. Department of Health and Human Services (HHS) on October 20, 2026, regarding a new strategy to revitalize American kidney care, which includes introducing competition measures into the domestic dialysis market. DaVita's stock subsequently fell by over 6.2% on the same day, prompting SBS to invite affected shareholders to join the fraud investigation.

Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses

https://www.benzinga.com/news/health-care/26/11/63206781/dialysis-giants-davita-and-fresenius-blocking-competition-in-washington-lawsuit-accuses
Washington Attorney General Nick Brown has filed a lawsuit against DaVita Inc. and Fresenius Medical Care Holdings Inc., accusing the dialysis providers of using illegal noncompete agreements. These agreements, allegedly forced upon medical directors, prevent competition and limit care options for approximately 9,000 kidney failure patients in Washington state. The lawsuit seeks to invalidate the noncompete agreements and impose penalties on the companies for violating state law.

DaVita Inc. stock underperforms Thursday when compared to competitors

https://www.marketwatch.com/data-news/davita-inc-stock-underperforms-thursday-when-compared-to-competitors-f9dcaf13-9790c8dfbc6d
Shares of DaVita Inc. (DVA) fell by 5.14% to $174.07 on Thursday, despite a general market downturn where the S&P 500 Index and Dow Jones Industrial Average also declined. The stock closed significantly below its 52-week high of $247.49 achieved on August 3rd.
Advertisement

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-davita-inc---dva-302937546.html
Pomerantz LLP is investigating DaVita Inc. (NYSE: DVA) on behalf of investors following a significant stock price drop. The investigation concerns potential securities fraud or unlawful business practices after the U.S. Department of Health and Human Services announced a new strategy to revitalize American kidney care, targeting the concentrated dialysis market and shifting incentives towards preventive care. This news led to DaVita's stock falling $11.65 per share, or 6.23%, on October 20, 2026.

DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law

https://markets.financialcontent.com/stocks/article/bizwire-2026-11-12-dva-investors-have-opportunity-to-join-davita-inc-fraud-investigation-with-sbs-law
Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations by DaVita Inc. (NYSE: DVA) on behalf of investors. The investigation stems from a U.S. Department of Health and Human Services announcement on October 20, 2026, regarding new competition measures in the domestic dialysis market, which caused DaVita's shares to fall over 6.2%. SBS encourages affected shareholders to join the fraud investigation.

CorMedix Beats A Lowered Bar As The DefenCath Cliff Arrives, And Heron Becomes The New Growth Story

https://finviz.com/news/421912/cormedix-beats-a-lowered-bar-as-the-defencath-cliff-arrives-and-heron-becomes-the-new-growth-story
CorMedix (CRMD) reported a Q3 earnings beat, exceeding expectations for both loss per share and revenue, but faced a significant decline in its DefenCath revenue. The company is pivoting towards an acquisition-led diversification strategy with the Heron acquisition, aiming to offset the collapsing DefenCath franchise. Despite reaffirming full-year 2026 revenue guidance and raising Adjusted EBITDA guidance, the long-term outlook for DefenCath remains uncertain, and the market has reacted negatively to the withdrawal of 2027 DefenCath guidance and acquisition risks.

Cintas/UniFirst: CFO Expresses Confidence in Deal Prospects as FTC Review Continues

https://thecapitolforum.com/cintas-unifirst-cfo-expresses-confidence-in-deal-prospects-as-ftc-review-continues/
Cintas CFO Scott Garula indicated confidence in the company's proposed $5.5 billion acquisition of UniFirst, despite ongoing engagement with the FTC regarding the deal. The announcement was made at an industry conference in Chicago. This suggests that Cintas is actively working with regulators to address any concerns.

DaVita Inc. stock underperforms Tuesday when compared to competitors

https://www.marketwatch.com/data-news/davita-inc-stock-underperforms-tuesday-when-compared-to-competitors-11e8b1b8-92477895f5e3
Shares of DaVita Inc. (DVA) fell 3.37% on Tuesday, closing at $179.28. This underperformance occurred during a generally negative trading session where the S&P 500 Index (SPX) declined by 0.38% and the Dow Jones Industrial Average (DJIA) fell by 0.30%. This marks the third consecutive day of losses for DaVita's stock.
Advertisement

DaVita Continues To Outperform Dialysis Peer Fresenius Medical Care

https://www.morningstar.com/company-reports/1509859-davita-continues-to-outperform-dialysis-peer-fresenius-medical-care
DaVita continues to outperform its dialysis peer, Fresenius Medical Care, according to Morningstar. The company, which focuses on services for end-stage renal disease patients primarily in the U.S., is expected to see brighter days ahead despite recent challenges related to COVID-19 mortality and labor pressures, and potential long-term impacts from obesity drugs.

Washington Sues Major Dialysis Providers Over Noncompete Agreements

https://www.dailyfly.com/2026/11/10/washington-sues-major-dialysis-providers-over-noncompete-agreements/
Washington State has filed a lawsuit against DaVita Inc. and Fresenius Medical Care Holdings Inc., two major dialysis providers, over alleged unlawful noncompete agreements. Attorney General Nick Brown claims these agreements, which restrict nephrologists serving as part-time medical directors from working at competing centers, limit competition and patient access to care for the approximately 9,000 Washington residents receiving dialysis. The state seeks to invalidate the agreements and impose financial penalties, with DaVita disputing the allegations.

DaVita Sees Growth and Drug Savings Offsetting 2027 Reimbursement Pressure

https://www.tradingview.com/news/marketbeat:71922e57d094b:0-davita-sees-growth-and-drug-savings-offsetting-2027-reimbursement-pressure/
DaVita (DVA) anticipates that increased dialysis treatment volumes and pharmaceutical cost reductions will help mitigate reimbursement pressures expected in 2027. Despite a projected $70 million pressure from a decline in commercial insurance mix, the company foresees opportunities in drug cost savings and improving treatment volume growth. DaVita is also accelerating a nationwide rollout of expanded hemodialysis dialyzers and plans to invest in growth, innovation, and share repurchases.

DaVita faces investigation over possible securities law violations after kidney care policy impacts its market.

https://pluang.com/en/news-feed/investigasi-davita-pelanggaran-hukum-sekuritas
DaVita Inc. is under investigation by Lowey Dannenberg, P.C. for potential federal securities law violations. This follows a new U.S. government strategy impacting the dialysis market, where DaVita is a key player, leading to a significant drop in its stock price. The investigation aims to determine if DaVita misled investors regarding regulatory and competitive risks.

$15M Davita data breach class action settlement

https://topclassactions.com/lawsuit-settlements/open-lawsuit-settlements/15m-davita-data-breach-class-action-settlement/
DaVita has agreed to a $15 million class action settlement to resolve claims stemming from a 2025 ransomware attack that exposed patient data. Class members affected by the data breach may receive a pro rata cash payment, estimated at $50, and can seek up to $2,500 for documented out-of-pocket losses related to identity theft or fraud. The settlement also includes three years of credit monitoring services.
Advertisement

DaVita HealthCare Partners (DVA) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/DVA.US
This article provides an in-depth analysis of DaVita HealthCare Partners (DVA) stock, covering its current price, market capitalization, quality and value scores, and historical performance. It details key financial figures, analyst expectations for growth, and valuation metrics, along with a "Belegger score" based on methodologies from investors like Buffett and Lynch. The analysis concludes with various price scenarios and a comparison with sector peers, emphasizing that the information is for informational purposes and not investment advice.

Vanguard, Fidelity Forecast a 50% Drop in US Stock Returns Amid Michael Burry's 'Lost Decades' Warning

https://www.ibtimes.co.uk/vanguard-fidelity-us-stock-return-forecasts-1831044
Vanguard and Fidelity are forecasting significantly lower annual returns for US stocks over the next one to two decades, with projections suggesting less than half the gains seen in the past decade. This cautious outlook aligns with investor Michael Burry's warning of potentially 15 to 20 years of negligible or negative inflation-adjusted returns, highlighting potential challenges for retirement planning and investment expectations. The forecasts contrast sharply with the S&P 500's performance over the last 10 years and emphasize the importance of realistic financial planning.

Cigna Group (CI) Could Be 54% Undervalued On Mixed Third Quarter Earnings

https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/cigna-group-ci-could-be-54-undervalued-on-mixed-third-quarte
Cigna Group (CI) reported mixed third-quarter 2026 results with higher sales and revenue but lower quarterly earnings, leading to a muted share price reaction. Despite recent caution, the stock has shown positive momentum over the past year. Simply Wall St's narrative suggests Cigna is 54% undervalued at $293.59 compared to a fair value of $636.28, primarily due to market concerns about political hostility towards PBMs and regulatory uncertainties.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA

https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-davita-inc---dva-302931455.html
Pomerantz LLP is investigating potential securities fraud claims against DaVita Inc. (NYSE: DVA) on behalf of its investors. This investigation follows a significant drop in DaVita's stock price after the U.S. Department of Health and Human Services announced a new strategy to revitalize American kidney care, which includes aggressive competition measures targeting dominant dialysis market players. Investors are encouraged to contact Pomerantz LLP for information on joining the class action.

What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:87621ef72094b:0-what-akebia-therapeutics-akba-said-on-its-q3-earnings-call/
Akebia Therapeutics (AKBA) reported lower Q3 revenue and a net loss due to declining Auryxia sales and inventory reductions for Vafseo, despite a significant increase in Vafseo patients. The company anticipates continued patient growth for Vafseo in Q4, with a focus on mid-sized dialysis providers and a slow rollout by larger organizations like DaVita ahead of a 2027 reimbursement change. Akebia also highlighted positive trial results for Vafseo and is exploring pipeline developments for other kidney diseases.
Advertisement

DaVita Inc. to Participate in Upcoming Investor Conferences

https://www.streetinsider.com/PRNewswire/DaVita+Inc.+to+Participate+in+Upcoming+Investor+Conferences/27281621.html
DaVita Inc. announced that its CFO, Joel Ackerman, and Group Vice President of Investor Relations, Nic Eliason, will participate in fireside chats at two upcoming investor conferences: the UBS Global Healthcare Conference 2026 on November 9, 2026, and the Wolfe Research Healthcare Conference 2026 on November 10, 2026. The company, a comprehensive kidney care provider, will make live webcasts of these presentations available for free registration.

DaVita Inc. (DVA) Seasonal returns chart

https://uk.finance.yahoo.com/quote/DVA/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for DaVita Inc. (DVA), showing the average monthly price return between 2016 and 2026. It also includes current stock information for DVA, such as its price and recent changes.

DaVita faces securities fraud investigation after kidney care reform plan hits its stock.

https://pluang.com/en/news-feed/peringatan-investor-pomerantz-lawan-selidiki-davita-inc-dva
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a significant drop in its stock price. This decline was triggered by a new federal kidney care strategy from the U.S. Department of Health and Human Services, which aims to increase competition and shift towards preventive care. The investigation could lead to legal action, impacting investors and the company's future.

DaVita Inc. to Participate in Upcoming Investor Conferences

https://www.tradingview.com/news/prnewswire:a17f0d09f43d4:0-davita-inc-to-participate-in-upcoming-investor-conferences/
DaVita Inc. announced that its CFO, Joel Ackerman, and Group VP of Investor Relations, Nic Eliason, will participate in fireside chats at two upcoming investor conferences: the UBS Global Healthcare Conference 2026 on November 9, 2026, and the Wolfe Research Healthcare Conference 2026 on November 10, 2026. The company, a comprehensive kidney care provider, will have its presentations webcast live from both events.

DaVita Inc. to Participate in Upcoming Investor Conferences

https://newsroom.davita.com/2026-11-03-davita-inc-to-participate-in-upcoming-investor-conferences/
DaVita Inc. announced that its Chief Financial Officer, Joel Ackerman, and Group Vice President of Investor Relations, Nic Eliason, will participate in fireside chats at two upcoming investor conferences: the UBS Global Healthcare Conference 2026 on November 9, 2026, and the Wolfe Research Healthcare Conference 2026 on November 10, 2026. The company, a comprehensive kidney care provider, highlighted its commitment to transforming care delivery and its extensive patient reach globally.
Advertisement

DaVita served about 298,100 dialysis patients by Sept. 30. Its finance chief will speak at two conferences Nov. 9-10.

https://www.stocktitan.net/news/DVA/da-vita-inc-to-participate-in-upcoming-investor-o5ubsf8k6bui.html
DaVita Inc. (NYSE: DVA) announced that its Chief Financial Officer, Joel Ackerman, and Group Vice President of Investor Relations, Nic Eliason, will participate in fireside chats at two upcoming healthcare investor conferences on November 9 and 10, 2026. The company, a leading kidney care provider, reported serving approximately 298,100 dialysis patients across 3,269 outpatient centers globally as of September 30, 2026. These conferences include the UBS Global Healthcare Conference and the Wolfe Research Healthcare Conference.

Lost Money on DaVita Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 6.23% Stock Decline

https://www.businesswire.com/news/home/20261103054009/en/Lost-Money-on-DaVita-Inc.-Shares-The-Law-Offices-of-Frank-R.-Cruz-Investigates-Potential-Securities-Fraud-After-6.23-Stock-Decline
The Law Offices of Frank R. Cruz announced an investigation into potential securities fraud claims against DaVita Inc. (NYSE: DVA) following a 6.23% stock decline on October 20, 2026. This drop occurred after the U.S. Department of Health and Human Services disclosed its Kidney Care National Plan, raising concerns about DaVita's market share and potential anticompetitive practices. Investors who suffered losses are encouraged to contact the firm to learn about potential claims.

U.S. Physical Therapy (USPH) reports earnings tomorrow: what to expect

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-3-us-physical-therapy-usph-reports-earnings-tomorrow-what-to-expect
U.S. Physical Therapy (USPH) is scheduled to report earnings this Wednesday after market close. Analysts expect revenue to grow by 8.7% year-on-year, a slowdown from the 17.3% growth in the same quarter last year. The company has a history of rarely missing Wall Street's revenue estimates, and investor sentiment in the healthcare providers & services segment has been positive recently.

DaVita Inc. (TRL.DE) cash flow

https://uk.finance.yahoo.com/quote/TRL.DE/cash-flow/
The article provides a financial overview of DaVita Inc. (TRL.DE), a company listed on XETRA. It highlights that the cash flow statement for the company is currently unavailable. The article also notes that financial statements will be updated on November 9th.

UBS raises DaVita stock price target to $287 on reimbursement outlook

https://ca.investing.com/news/stock-market-news/ubs-raises-davita-stock-price-target-to-287-on-reimbursement-outlook-93CH-4921264
UBS has increased its price target for DaVita Inc. (NYSE:DVA) shares to $287 from $270, maintaining a Buy rating, citing an improved reimbursement outlook. The firm anticipates a rise in phosphate binder operating income in 2027 and estimates an effective 2027 Medicare update of 1.5% to 2%. Despite recent positive third-quarter earnings that surpassed expectations, investor sentiment remains cautious due to concerns over cost pressures and long-term growth strategies.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement